Shoib Siddiqui

Dr. Shoib Siddiqui is a Senior Lecturer at the University of Hertfordshire's School of Life and Medical Sciences, specializing in cancer biology, immunology, and glycobiology. Previously, he held positions at the American University of Ras Al Khaimah and conducted postdoctoral research at UC San Diego under Prof. Ajit Varki. His research focuses on sialic acids, Siglecs, and microRNA mechanisms in cancer, Alzheimer’s, and sepsis. He earned his Ph.D. from ETH Zurich, investigating neuropilin-2 in skin cancer progression.

Education:

• Ph.D. in Vascular Biology, Immunology, and Cancer Biology (ETH Zurich, 2009–2013)
• M.Sc. in Biotechnology (IIT Bombay, 2008)

Research Focus: Dr. Siddiqui’s work explores cancer progression pathways, tumor biomarkers, and novel therapies. Key areas include Siglec-sialoglycan interactions, microRNA targeting, and drug repurposing for colorectal cancer. His recent projects involve developing RNAi therapeutics and inhibitors for Siglec-15.

Projects:

• Fluralaner as a Colorectal Cancer Therapeutic (2026–2027)
• ADAMTS-7 Inhibition for Coronary Artery Disease (2022)
• UK-China Mycotoxin Reduction Alliance (2022–2023)

Publications: Over 39 peer-reviewed articles in journals like Journal of Clinical Investigation, PNAS, and Blood, with a focus on oncology, glycobiology, and immunology. Recent trends emphasize Siglec-targeted therapies, microRNA networks, and drug repurposing strategies.

Awards: No formal awards listed, but noted for impactful publications in high-impact journals.

Advising & Grants: Served as Principal Investigator (PI) on RNAi therapeutics and Co-Investigator (CoI) on Siglec-15 and ADAMTS-7 projects. Collaborations span international institutions and cross-disciplinary teams.

Labs/Teams: Active in the Biosciences Research Group and Centre for Research in Mechanisms of Disease and Drug Discovery at UH. Collaborates with global researchers in glycobiology and oncology.